CARTITUDE-1: Redefining the Trajectory of Treatment for Relapsed/Refractory Multiple Myeloma (RRMM)

home / between-the-lines / cartitude-1-redefining-the-trajectory-of-treatment-for-relapsed-refractory-multiple-myeloma-rrmm

Panelists discuss how 5-year follow-up data from the CARTITUDE-1 study demonstrate that chimeric antigen receptor T-cell therapy with ciltacabtagene autoleucel achieved durable remissions in heavily pretreated patients with multiple myeloma, with 30% remaining progression free at 5 years and some patients achieving what may be considered a functional cure, potentially transforming multiple myeloma from an incurable to a curable disease.

2 experts are featured in this series.

EP. 1: Treatment Approaches in Multiple Myeloma

Peter Voorhees, MD;Sundar Jagannath, MD
June 27th 2025

Panelists discuss how advancements in treatment options, including chimeric antigen receptor (CAR) T-cell therapy, bispecific antibodies, and antibody-drug conjugates, are shaping the current multiple myeloma landscape.

2 experts are featured in this series.

EP. 2: FDA Approvals for Multiple Myeloma

Peter Voorhees, MD;Sundar Jagannath, MD
June 27th 2025

Panelists discuss how the evolution of FDA approvals for multiple myeloma therapies reflects rapid innovation and increasing effectiveness, particularly with cell-based treatments.